Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ELIC.ST
- Price
- 3.06
- Stock movement up
- +0.10 (3.55%)
- Company name
- Elicera Therapeutics AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 107.39M
- Ent value
- 84.49M
- Price/Sales
- 26.51
- Price/Book
- 4.59
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 146.77%
- 3 year return
- -10.23%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
ELIC.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.51 |
| Price to Book | 4.59 |
| EV to Sales | 20.86 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 35.09M |
| EPS (TTM) | -0.39 |
| FCF per share (TTM) | -0.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.05M |
| Gross profit (TTM) | 4.04M |
| Operating income (TTM) | -19.21M |
| Net income (TTM) | -18.26M |
| EPS (TTM) | -0.39 |
| EPS (1y forward) | -1.07 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.78% |
| Operating margin (TTM) | -474.26% |
| Profit margin (TTM) | -450.61% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.63M |
| Net receivables | 0.00 |
| Total current assets | 31.11M |
| Goodwill | 0.00 |
| Intangible assets | 2.94K |
| Property, plant and equipment | 0.00 |
| Total assets | 31.11M |
| Accounts payable | 541.21K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 7.74M |
| Total liabilities | 7.74M |
| Shareholder's equity | 23.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.73M |
| Capital expenditures (TTM) | 1.00K |
| Free cash flow (TTM) | -15.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.11% |
| Return on Assets | -58.68% |
| Return on Invested Capital | -78.11% |
| Cash Return on Invested Capital | -67.29% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.95 |
| Daily high | 3.06 |
| Daily low | 2.90 |
| Daily Volume | 150K |
| All-time high | 8.56 |
| 1y analyst estimate | 2.50 |
| Beta | -0.42 |
| EPS (TTM) | -0.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 16 May 2025 |
Downside potential
Loading...
Downside potential data
| ELIC.ST | S&P500 | |
| Current price drop from All-time high | -64.25% | -12.89% |
| Highest price drop | -90.05% | -56.47% |
| Date of highest drop | 15 May 2024 | 9 Mar 2009 |
| Avg drop from high | -57.31% | -11.07% |
| Avg time to new high | 139 days | 12 days |
| Max time to new high | 933 days | 1805 days |
COMPANY DETAILS
Marketcap
107.39M
Marketcap category
Small-cap
Description
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Employees
2
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found